History

2004

2004

•  Evive Biotech founded
2004
2005

2005

  • Filed the first patent for rhIL-22
2005
2007

2007

• Early development of therapeutic rhIL-22

2007

2009

• Established DikineTM platform and initiated F-652 (rhIL-22 dimer) project

• Completed F-627 preclinical studies

 

2009

2010

•  Initiated and completed Ph I study for F-627

2010

2011

•  F-627 CMO manufacturing in US

2011

2012

•  Received F-627 China IND approval

•  Initiated F-627 Ph II study in US and Europe

•  Launched cGMP manufacturing plant project

2012

2014

• Completed F-627 Ph II study in US and Europe
• Initiated F-627 China Ph II study

2014

2015

• Initiated two Ph II studies in US for F-652 to treat patients with GvHD (acute graft versus host disease) and AH (acute alcoholic hepatitis)

• Completed F-627 China Phase II study

• Received F-652 China IND approval

• Completed F-627 first GMP run

2015

2016

• F-627 US Ph III IND approval
• Initiated F-627 Ph III study (04) in US and Europe

2016

2017

• F-627 SPA agreement with U.S. FDA

• F-627 China Ph III IND approval

• Completed F-652 China Ph I study

2017

2018

• F-627 Ph III study (04) met primary and secondary end points
• Initiated F-627 second global Ph III study (05)
• Completed F-652 Ph IIa study to treat AH

2018

2019

• Received Orphan-Drug Designation from U.S. FDA for F-652 for the treatment of Acute Graft vs Host Disease

2019

2020

• F-627 China Ph III study met primary endpoints
• Completed F-652 Ph IIa study to treat GvHD
• F-627 second global Ph III study (05) met primary endpoints
• Rebranded Generon to Evive Biotech

2020

2021

• Formed joint venture with Dr. Xiao Qiang Yan to further develop bi-specific antibody platform ITab™

2021